Increased Early Revision Rate With the INFINITY Total Ankle Prosthesis.

Journal Article (Journal Article)

BACKGROUND:: A number of new 2-component total ankle arthroplasty systems that emphasize minimal bone resection have been introduced for which few clinical outcomes reports are available. Our aim was to identify the rate of early revision among patients receiving the 2-component INFINITY prosthesis. METHODS:: Patients from 2 prospectively collected databases at the authors' institution were screened for inclusion in the present study. All patients who underwent a primary total ankle arthroplasty (TAA) with the INFINITY prosthesis and who were at least 1 year postoperative were included. A total of 159 ankles with a mean 20 months of follow up (range, 12-37) met these criteria. All surgeries were performed by 1 of 2 orthopedic foot and ankle surgeons with extensive experience in TAA. The primary outcome was the need for revision surgery, defined as removal of 1 or both metal components. Peri-implant lucency at most recent follow-up was a secondary outcome. Weightbearing radiographs at most recent follow-up were graded for lucency independently by 2 reviewers. RESULTS:: Sixteen ankles (10%) underwent revision at a mean 13 months postoperatively. The most common reasons for revision were symptomatic tibial component loosening and deep infection (6 patients each, 3.8%). Of the 108 ankles with retained components and at least 1 year of radiographic follow-up, 8 (7.4%) had global lucency around the tibial component suggestive of loosening at most recent follow-up. CONCLUSIONS:: Our initial review of patients undergoing TAA with this new 2-component prosthesis demonstrates an elevated early revision rate due to tibial component loosening compared to other implant systems. LEVEL OF EVIDENCE:: Level IV, case series.

Full Text

Duke Authors

Cited Authors

  • Cody, EA; Taylor, MA; Nunley, JA; Parekh, SG; DeOrio, JK

Published Date

  • January 2019

Published In

Volume / Issue

  • 40 / 1

Start / End Page

  • 9 - 17

PubMed ID

  • 30175612

Electronic International Standard Serial Number (EISSN)

  • 1944-7876

Digital Object Identifier (DOI)

  • 10.1177/1071100718794933


  • eng

Conference Location

  • United States